Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Readmission after colectomy for cancer predicts one-year mortality.

Greenblatt DY, Weber SM, O'Connor ES, LoConte NK, Liou JI, Smith MA.

Ann Surg. 2010 Apr;251(4):659-69. doi: 10.1097/SLA.0b013e3181d3d27c.

2.
3.

Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.

Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD.

J Am Geriatr Soc. 2009 Aug;57(8):1403-10. doi: 10.1111/j.1532-5415.2009.02355.x. Epub 2009 Jun 25.

PMID:
19563521
4.

Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women.

Hershman DL, Buono D, McBride RB, Tsai WY, Neugut AI.

Cancer. 2009 Sep 1;115(17):3848-57. doi: 10.1002/cncr.24448.

5.

Clinical implications of microsatellite instability in sporadic colon cancers.

Sinicrope FA, Sargent DJ.

Curr Opin Oncol. 2009 Jul;21(4):369-73. doi: 10.1097/CCO.0b013e32832c94bd. Review.

6.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A.

J Clin Oncol. 2009 Feb 20;27(6):872-7. doi: 10.1200/JCO.2008.19.5362. Epub 2009 Jan 5.

7.

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.

Sharif S, O'Connell MJ, Yothers G, Lopa S, Wolmark N.

Cancer Invest. 2008 Nov;26(9):956-63. doi: 10.1080/07357900802132550. Review.

8.

Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer.

Bradley CJ, Given CW, Dahman B, Fitzgerald TL.

Arch Intern Med. 2008 Mar 10;168(5):521-9. doi: 10.1001/archinternmed.2007.82.

PMID:
18332299
9.

Identification of patients with high-risk stage II colon cancer for adjuvant therapy.

Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR.

Dis Colon Rectum. 2008 May;51(5):503-7. doi: 10.1007/s10350-008-9246-z. Epub 2008 Mar 6.

PMID:
18322753
10.

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ.

Lancet. 2007 Dec 15;370(9604):2020-9.

PMID:
18083404
12.

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.

Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ; National Cancer Institute.

J Clin Oncol. 2007 Mar 1;25(7):767-72. Epub 2007 Jan 16.

PMID:
17228023
14.

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW.

Nat Genet. 2006 Jul;38(7):787-93. Epub 2006 Jun 25.

PMID:
16804544
15.

Completion of therapy by Medicare patients with stage III colon cancer.

Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W.

J Natl Cancer Inst. 2006 May 3;98(9):610-9.

16.

Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer.

Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML.

Gastroenterology. 2005 Sep;129(3):837-45.

PMID:
16143123
17.

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG.

J Clin Oncol. 2004 Aug 15;22(16):3408-19. Epub 2004 Jun 15. Review.

PMID:
15199089
18.

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators.

N Engl J Med. 2004 Jun 3;350(23):2343-51.

19.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.

PMID:
15067028
20.

Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG.

J Clin Oncol. 2003 Aug 1;21(15):2912-9.

PMID:
12885809

Supplemental Content

Support Center